Celldex Therapeutics (CLDX) Other Non-Current Assets (2010 - 2026)

Celldex Therapeutics' Other Non-Current Assets history runs 17 years deep, the most recent figure standing at $15.4 million for Q1 2026.

• In Q1 2026, Other Non-Current Assets rose 48.28% year-over-year to $15.4 million; the TTM figure through Mar 2026 stood at $15.4 million (up 48.28% YoY), while the FY2025 annual figure was $13.4 million, up 37.05% from the prior year.
• Other Non-Current Assets for Q1 2026 stood at $15.4 million, up from $13.4 million in the prior quarter.
• The five-year high for Other Non-Current Assets was $15.4 million in Q1 2026, with the low at $104000.0 in Q1 2022.
• The 5-year median for Other Non-Current Assets is $107000.0 (2023), against an average of $4.6 million.
• Peak annual rise in Other Non-Current Assets reached 9628.04% in 2025, while the deepest fall reached 3.93% in 2025.
• Celldex Therapeutics' Other Non-Current Assets stood at $104000.0 in 2022, then advanced by 2.88% to $107000.0 in 2023, then soared by 9009.35% to $9.7 million in 2024, then soared by 37.05% to $13.4 million in 2025, then increased by 15.54% to $15.4 million in 2026.
• Business Quant data shows CLDX's Other Non-Current Assets at $15.4 million in Q1 2026, $13.4 million in Q4 2025, and $9.4 million in Q3 2025.